Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.63 |
| ▸ | HTR1A | P08908 | 13/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.62 |
| ▸ | HRH1 | P35367 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22266112 | 0.98 | SLC6A2 (0.61) | SLC6A2HTR1ASLC6A3SLC6A4HRH1 | |
| SCHEMBL20615067 | 0.83 | SLC6A2 (0.70) | SLC6A2HTR1ASLC6A3SLC6A4HRH1 | |
| SCHEMBL3080032 | 0.83 | SLC6A2 (0.57) | SLC6A2HTR1ASLC6A3SLC6A4HRH1 | |
| SCHEMBL234010 | 0.83 | SLC6A2 (0.81) | SLC6A2HTR1ASLC6A3SLC6A4HRH1 | |
| Hydrochloric Acid SCHEMBL4095144 | 0.82 | SLC6A2 (0.56) | SLC6A2HTR1ASLC6A3SLC6A4HRH1 | |
| Hydrochloric Acid SCHEMBL3466964 | 0.81 | SLC6A2 (0.79) | SLC6A2HTR1ASLC6A3SLC6A4HRH1 | |
| SCHEMBL22278138 | 0.81 | SLC6A2 (0.62) | SLC6A2HTR1ASLC6A3SLC6A4HRH1 | |
| SCHEMBL11069093 | 0.81 | SLC6A2 (0.63) | SLC6A2HTR1ASLC6A3SLC6A4HRH1 | |
| SCHEMBL31071563 | 0.80 | SLC6A2 (0.48) | SLC6A2HTR1ASLC6A3SLC6A4HRH1 | |
| SCHEMBL11063123 | 0.79 | SLC6A2 (0.61) | SLC6A2HTR1ASLC6A3SLC6A4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021097240-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
| WO-2020154571-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | SLC6A2 520/4885HTR1A 2446/4885SLC6A3 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.